Search results
Results from the WOW.Com Content Network
Adjuvant chemotherapy has been used in malignant melanoma, but there is little hard evidence to use chemotherapy in the adjuvant setting. However, melanoma is not a chemotherapy-resistant malignancy. Dacarbazine, temozolomide, and cisplatin all have a reproducible 10–20% response rate in metastatic melanoma.
Neoadjuvant therapy is the administration of therapeutic agents before a main treatment. One example is neoadjuvant hormone therapy prior to radical radiotherapy for adenocarcinoma of the prostate. Neoadjuvant therapy aims to reduce the size or extent of the cancer before using radical treatment intervention, thus both making procedures easier ...
Neoadjuvant chemotherapy is given prior to a local treatment such as surgery, and is designed to shrink the primary tumor. [6]: 55–59 It is also given for cancers with a high risk of micrometastatic disease. [8]: 42 Adjuvant chemotherapy is given after a local treatment (radiotherapy or surgery). It can be used when there is little evidence ...
Treatment before surgery is often described as neoadjuvant. In breast cancer, the survival rate of patients who receive neoadjuvant chemotherapy are no different from those who are treated following surgery. [8] Giving chemotherapy earlier allows oncologists to evaluate the effectiveness of the therapy, and may make removal of the tumor easier.
Adjuvant chemotherapy. Adjuvant chemotherapy is given after surgery to reduce the risk of recurrence. It is used to try to kill any cancer cells that might still exist and cannot be detected through imaging tests. [2] Palliative chemotherapy Palliative chemotherapy is used to control (but not cure) the cancer in settings in which the cancer has ...
Neoadjuvant chemotherapy (before surgery) is very frequently used for triple-negative breast cancers as they are more susceptible to platinum-based regimen, allowing for a higher rate of breast-conserving surgeries. Important details on the individual responsiveness of particular cancers can be gained from evaluating the response to this form ...
[1] [2] [3] As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively (neoadjuvant chemotherapy) and postoperatively (adjuvant chemotherapy).
Endocrine therapy is usually administered after surgery, chemotherapy, and radiotherapy have been given, but can also occur in the neoadjuvant or non-surgical setting. Hormonal treatments include antiestrogen therapy, but also to a lesser extent, and/or more in the past, estrogen therapy and androgen therapy.